• Protecting the people of the Americas through vaccination.

PAHO Revolving Fund

For more than 40 years, PAHO’s Revolving Fund for Access to Vaccines, has provided access to safe and quality vaccines at affordable prices for Member States and Territories throughout the region. It is part of PAHO's larger technical cooperation package that supports countries' efforts to achieve sustainable and equitable reduction of morbidity and mortality of vaccine-preventable diseases through control and elimination strategies.

By consolidating forecasted demand requirements and leveraging economies of scale, promoting transparent negotiations with suppliers, and implementing innovative acquisition strategies, the Revolving Fund, greatly improves its purchasing power; lowering vaccine prices and contributing to the sustainability of National Immunization Programs.



Revolving Fund Prices

Technical Cooperation

The Revolving Fund (RFV) provides technical cooperation to national immunization programs to improve their vaccine demand planning and forecasting capacities, strengthen supply chain management, and ensure their financing and sustainability. This cooperation is aligned with the recommendations and guidelines of PAHO’s technical program, the Comprehensive Immunization Special Program (CIM).

Through timely supply, the Revolving Fund has supported participating Member States by:

  • Elimination of polio, measles, rubella.
  • Maintaining vaccination coverage of over 80%.
  • Covering over 95% of Member States’ vaccination costs with their national budgets.

Unique Benefits of the Revolving Fund

  • Countries would have paid at least 75% more for the Region's 13 most used routine vaccines
  • Continuous support from Member States
  • More than 40 years of experience
  • WHO-prequalified vaccines and high-quality, efficacious recommended products

COVID-19 Pandemic

Component 1: The COVAX Facility

PAHO supports the global access efforts within the “WHO Access to COVID-19 Tools Accelerator (ACT)” and its vaccine pillar COVAX through its Revolving Fund. The COVAX Facility is the only global initiative that works with governments and manufacturers to ensure safe and effective COVID-19 vaccines are available to the highest risk populations worldwide, regardless of income level. Member States participating in the COVAX Facility through the PAHO Revolving Fund are recognized as a regional bloc. 36 countries and territories in Latin America and the Caribbean are participating in the COVAX Facility. There are two groups of participating countries in the COVAX facility:

  • Self-financed countries: Member States that are maintaining and self-financing their immunization programs.
  • COVAX Advanced Market Commitment (AMC) countries: Ten countries and territories in the Region are eligible for support from the COVAX AMC: Bolivia, Dominica, El Salvador Grenada, Guyana, Haiti, Honduras, Nicaragua, St. Lucia, St. Vincent & the Grenadines. AMC countries receive their doses at no cost to cover  20% of their population.

PAHO’s Role in the COVAX facility

Under the COVAX Facility, PAHO RF is the designated procurement agency wi for all interested Member States in the Region of the Americas. In close collaboration with UNICEF, the PAHO RF has been assisting the implementation of the procurement strategy for the COVAX Facility.

The Revolving Fund has also been assisting countries in:

  • Assisting countries in understanding and preparing to meet the COVAX requirements, including financial, legal, programmatic, regulatory, among others.
  • Updating countries about market dynamics and financial projections to estimate their investment in COVID-19 vaccines.
  • Forecasting and securing supplies related to vaccine administration, such as syringes and safety boxes.
  • Supporting regular demand planning  so that routine immunization programs can continue safely.
  • Under certain conditions when bridge funding is required to access COVID-19 vaccine doses in a timely manner, the Revolving Fund is working with countries to extend financial credits.
  • Channeling down payments to Gavi, the Vaccine Alliance, for countries with administrative restrictions.
  • International bidding and joint tender with UNICEF, establishing long-term agreements with suppliers to issue price estimates, purchase orders, and requisitions in record time.
  • Coordinating and monitoring international logistics for 36 countries in the Americas region. 
  • Advocating for donations to the Region and supporting coordination and country readiness.

For more information on the COVAX Facility, visit Gavi: COVAX facility and WHO: COVAX facility 

Component 2: Donations

PAHO has been advocating for more doses to be donated to the region of the Americas and through its Revolving Fund has been proactively involving in planning and operations along with the US government for its bilateral donations and COVAX donated doses from Sweden, Norway, Spain, and Canada, among others. The Revolving Fund is providing guidance to direct the resources to the most needed and expediting and removing bottlenecks with donors.

Component 3: Regional access to additional COVID-19 vaccine 

As requested by Member States (MS), through its RF, PAHO is working to facilitate regional access to additional COVID-19 for MS during Q4, 2021 and 2022. Leveraging more than 40 years of experience, PAHO is seeking to improve market dynamics for the Region by applying its principles of quality assurance, pooling, and solidarity. The RF’s objective is to amplify its support, on behalf of MS to access vaccine supply by consolidating demand and guiding countries through market dynamics and innovative financial considerations to meet their vaccine needs.

For more information on the COVAX Facility, visit Gavi: COVAX facility and WHO: COVAX facility 

Some countries in the Region have negotiated directly with manufacturers of COVID-19 bilaterally or are procuring directly their COVAX doses. Countries may also access COVID-19 vaccines through the COVAX Facility using the Revolving Fund as the procurement agent.

Regardless of whether PAHO’s Member States have joined the COVAX Facility through the Revolving Fund, they will continue to receive PAHO’s support for the introduction of COVID-19 vaccines, including vaccine demand planning, logistics, and cold chain management, strengthening surveillance of Adverse Effects Following Immunization (AEFI) and information systems, training of health care workers, generating vaccine demand, and guiding risk and strategic communication strategies and tools

Donor countries can reach out to their PAHO representative for the Americas region, write and/or email rfv@paho.org. To donate through COVAX, contact the administration of the COVAX facility at Gavi. To request additional information at contact us at covax@gavi.org.  

Revolving Fund Product Portfolio

The PAHO Revolving Fund Product Portfolio is the collection of products offered to the Countries and territories in Latin America and the Caribbean to be used in the Immunization Programs. The Portfolio includes product detailed information to support Member States with the procurement planning.

Biological products

Biological Products

Syringe

Syringes AD and Disposable

Cold chain

Other Products

  • BCG
  • Cholera
  • DPT (pediatric)
  • DPT Hib Lyophilized (Pediatric)
  • DTwP-HepB+Hib (Pentavalent) Liquid (Pediatric)
  • dT (Adult) - DT (Pediatric)
  • Tdap Triple Acellular Adolescent/Adult
  • DTaP Triple Acellular (Pediatric)
  • DTaP-IPV (Tetravalent
  • DTaP-IPV-Hib (Pentavalent Acellular) (Pre-filled Syringe) Acellular) (Pre-filled Syringe)
  • DTaP-IPV-Hep B-Hib (Hexavalent Acellular)
  • Hepatitis "A" Adult (Vial and Pre-filled Syringe)
  • Hepatitis "A" Pediatric
  • Hepatitis B Recombinant Adult
  • Hepatitis B Recombinant Pediatric
  • Hib Lyophilized - Meningococcal ACYW135
  • Inactivated Polio (IPV) - Seasonal Influenza Vaccine
  • Measles-Rubella - Measles/Mumps (Jeryl-Lynn)/Rubella
  • Measles/Mumps (Zagreb)/Rubella
  • Oral Polio Bivalent (bOPV)
  • Pneumococcal Conjugated Pediatric
  • 10 Valent (PCV-10)
  • Pneumococcal Conjugated Pediatric
  • 13 Valent (PCV-13)
  • Pneumococcal Unconjugated Adult
  • 23 valent
  • Rabies Canine
  • Rabies Vaccine Human Use / Vero Cells - Rotavirus Liquid (2 dose immunization scheme) - Typhoid Polysaccharide - Varicella - Yellow Fever

Syringe of single use with a re-use prevention feature in a blister packed with fixed needle.

  • Pre-qualified: Yes E008/
  • Presentation: Box x 100 pcs
  • Shelf life: Minimum 24 months at time of shipment (total shelf life 52 months)
  • Syringe Price: Link prices 2019
  • Mode of transportation:
    • Air: quantities under 200,000 pcs
    • Ocean: quantities above 200,000 pcs
  • Storage Conditions: between 15 and 25 °C
  • Estimate Delivery time:
    • Air - Confirmed in annual demand: 6 - 8 weeks after placing purchase order
    • Ocean - Confirmed in annual demand: 12 - 13 weeks after placing purchase order
    • Air - Additional demand: 10 – 12 weeks after placing purchase order
    • Ocean - Additional demand: 16 – 18 weeks after placing purchase order
  • Syringe Availability overview in the region: there is enough supply to meet the confirmed requirements of our Members for 2019. Suppliers are reliable and with enough production capacity in case of an increase in the demand.

 

 

 

 

 
Protecting the people of the Americas through vaccination.

News

Documents

Communications Materials

All

Mandates and Strategies

All